... including cell and gene therapy,” Jakob Dupont, the head of global research and development at Atara, said in a statement.
https://www.google.com/url?rct=j&sa=t&url=https://www.sfvbj.com/healthcare/atara-biotherapeutics-stock-enjoys-rebound/&ct=ga&cd=CAIyGmEyNDJjNTAxZWU3OTQyNzI6Y29tOmVuOlVT&usg=AOvVaw284BnLKhruYlkiZ198tn1d
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.